Heron Therapeutics | HRTX - Operating Expenses

Stock Price
1.20
Daily Change
-0.08 -5.91%
Monthly
-19.80%
Yearly
-28.01%
Q1 Forecast
2.71

Heron Therapeutics reported $38.47M in Operating Expenses for its fiscal quarter ending in September of 2024.





Operating Expenses Change Date
ALKERMES USD 1.73B 1.44B Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amarin USD 51.37M 14.6M Sep/2025
ANI Pharmaceuticals USD 505.82M 309.62M Sep/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 223.22M 10.86M Dec/2025
Eisai JPY 199.9B 16.22B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Heron Therapeutics USD 38.47M 4M Sep/2024
Insmed USD 403.69M 42.4M Sep/2025
Ligand Pharmaceuticals USD 8.29M 32.17M Sep/2025
Merck USD 10.16B 558M Dec/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 166.36M 4.5M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Surmodics USD -245.35M 363.49M Sep/2024
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Veracyte USD 108.76M 7.09M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025